Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment

婴儿型ε-肌聚糖(SGCE)肌阵挛-肌张力障碍:诊断陷阱和药物治疗反应不佳

阅读:2

Abstract

Myoclonus in infancy is often benign; however, persistent or progressive forms may indicate an underlying neurologic disease, including genetic movement disorders such as myoclonus-dystonia syndrome, a rare genetic condition most often associated with pathogenic variants in the Epsilon-Sarcoglycan (SGCE) gene. Early-onset cases are particularly challenging due to overlap with benign, epileptic, and metabolic conditions. We report a six-year-old girl with myoclonus beginning at 12 months of age, involving her head, neck, and arms, and a delayed onset of mild dystonia at five years. Neurological examination, neuroimaging, electroencephalography, and metabolic investigations were unremarkable. Genetic testing identified a heterozygous pathogenic SGCE variant, confirming the diagnosis. Trials with zonisamide, carbamazepine, sodium valproate, and clonazepam were ineffective; however, motor and cognitive development remained within the average range. Behavioral and attentional difficulties emerged later in childhood. This case highlights the diagnostic challenges of early-onset SGCE myoclonus-dystonia presenting as isolated myoclonus. Genetic testing was essential for diagnosis, pharmacologic response was limited, and functional outcome remained favorable. The later emergence of behavioral symptoms underscores the need for long-term multidisciplinary follow-up.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。